^
    2d
    AB154 Combined With AB122 for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=46, Recruiting, Yale University | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Feb 2025 --> Jul 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    4d
    SKYSCRAPER-04: A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (clinicaltrials.gov)
    P2, N=172, Active, not recruiting, Hoffmann-La Roche | Trial completion date: May 2024 --> Dec 2024
    Trial completion date • Metastases
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    7d
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (clinicaltrials.gov)
    P2, N=42, Recruiting, Georgetown University | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    7d
    A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody. (PubMed, Sci Rep)
    The tumor volume inhibition rate for ZGGS15 at 2 mg/kg was 69.70%, and for ZGGS15 at 5 mg/kg plus nivolumab at 1 mg/kg, it was 94.03% (p < 0.001). Our data reveal that ZGGS15 exhibits potent anti-tumor efficacy without eliciting ADCC or CDC or causing cytokine production, therefore having a safe profile.
    Preclinical • Journal • Combination therapy
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
    |
    Opdivo (nivolumab) • ZGGS15
    11d
    Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma (clinicaltrials.gov)
    P2, N=26, Recruiting, Diwakar Davar | Trial completion date: Jan 2028 --> Jan 2030 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    BRAF mutation
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    11d
    A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) (clinicaltrials.gov)
    P3, N=1560, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • vibostolimab/pembrolizumab (MK-7684A)
    16d
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (clinicaltrials.gov)
    P1/2, N=110, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=336 --> 110 | Trial completion date: Jul 2025 --> Mar 2024 | Trial primary completion date: Jan 2025 --> Sep 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    16d
    A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01) (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial • Combination therapy • Tumor mutational burden
    |
    favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    17d
    MST01-AZN-05: PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Recruiting, Presage Biosciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    17d
    EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=10, Completed, M.D. Anderson Cancer Center | Recruiting --> Completed | N=20 --> 10 | Trial completion date: Dec 2025 --> Apr 2024
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Checkpoint inhibition
    |
    Opdivo (nivolumab) • etigilimab (OMP-313M32)
    24d
    ARTEMIDE-01: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1/2, N=179, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    rilvegostomig (AZD2936)
    29d
    Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) (clinicaltrials.gov)
    P1, N=492, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2024 --> Aug 2024 | Trial primary completion date: Oct 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
    29d
    Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. (clinicaltrials.gov)
    P1/2, N=93, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial • Combination therapy • Metastases
    |
    cisplatin • etoposide IV • ZG005
    29d
    Rethinking strategies in SCLC: Lessons learned from tiragolumab in the SKYSCRAPER-02 study. (PubMed, Med)
    The addition of tiragolumab, an anti-TIGIT inhibitor, to chemotherapy plus atezolizumab demonstrated promising early results for lung cancer. Unfortunately, the phase 3 study SKYSCRAPER-02 did not confirm the anticipated benefit of tiragolumab combination in recalcitrant small-cell lung cancer,1 reiterating the need for a more accurate population selection in clinical trials.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    30d
    IMperator: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (clinicaltrials.gov)
    P2, N=40, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Presage Biosciences
    New P1 trial
    |
    Keytruda (pembrolizumab) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    1m
    AB154 Combined With AB122 for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=46, Recruiting, Yale University | Trial completion date: Dec 2025 --> Feb 2025
    Trial completion date • Combination therapy
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    1m
    A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Bristol-Myers Squibb | N=75 --> 4
    Enrollment change • Combination therapy • Metastases
    1m
    TROPION-Lung10: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=675, Not yet recruiting, AstraZeneca
    New P3 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    TROP2 positive
    |
    Keytruda (pembrolizumab) • datopotamab deruxtecan (DS-1062a) • rilvegostomig (AZD2936)
    1m
    A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=225, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • carboplatin • paclitaxel • docetaxel
    1m
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2; Recruiting --> Active, not recruiting
    Combination therapy • Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    1m
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=720, Recruiting, Gilead Sciences | Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2027 --> Sep 2027
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    1m
    Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, SCRI Development Innovations, LLC | Trial completion date: Feb 2024 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    1m
    A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. (clinicaltrials.gov)
    P2, N=117, Not yet recruiting, Shanghai Henlius Biotech
    New P2 trial • Metastases
    |
    Hansizhuang (serplulimab) • HLX-53 • Hanbeitai (bevacizumab biosimilar)
    1m
    AdvanTIG-203: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=125, Completed, BeiGene | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tevimbra (tislelizumab) • ociperlimab (BGB-A1217)
    1m
    A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=101, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=241 --> 101 | Trial completion date: Feb 2025 --> Jan 2024
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986207
    1m
    NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, The Netherlands Cancer Institute
    New P2 trial
    |
    Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058)
    2ms
    Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • ZG005
    2ms
    A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial primary completion date: Aug 2024 --> Dec 2024
    Enrollment closed • Enrollment change • Trial primary completion date • Metastases
    |
    HLX-53
    2ms
    Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=16, Terminated, iTeos Belgium SA | N=162 --> 16 | Trial completion date: Dec 2025 --> Nov 2023 | Recruiting --> Terminated; Company operational decision. Decision to stop study is not due to safety or efficacy concerns
    Enrollment change • Trial completion date • Trial termination • Combination therapy
    |
    dexamethasone • iberdomide (CC-220) • belrestotug (EOS-448)
    2ms
    EDGE-Gastric: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (clinicaltrials.gov)
    P2, N=360, Recruiting, Arcus Biosciences, Inc. | N=200 --> 360 | Trial completion date: Nov 2025 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)
    2ms
    IMperator: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Hoffmann-La Roche
    New P2 trial • Tumor mutational burden
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Tumor mutational burden • IO biomarker
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov)
    P1, N=143, Recruiting, Akesobio Australia Pty Ltd | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    Kaitanni (cadonilimab) • AK127
    2ms
    A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer) (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Aug 2027 --> Aug 2024 | Trial primary completion date: Nov 2026 --> Aug 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • tiragolumab (RG6058)
    2ms
    Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3; Recruiting --> Active, not recruiting | N=750 --> 169
    Enrollment change • Enrollment closed • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    2ms
    A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ) (clinicaltrials.gov)
    P2, N=29, Terminated, Hoffmann-La Roche | Active, not recruiting --> Terminated; Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.
    Trial termination • Metastases
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PD-L1 expression • TIGIT expression
    |
    Tecentriq (atezolizumab) • capecitabine • oxaliplatin • tiragolumab (RG6058)
    2ms
    Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab. (PubMed, Structure)
    TIGIT is mainly expressed on T cells and is an inhibitory checkpoint receptor that binds to its ligand PVR in the tumor microenvironment. In contrast, Tiragolumab does not show an acidic pH-dependent binding enhancement. Our results provide valuable information that could help to improve the efficacy of therapeutic antibodies for cancer treatment.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    ociperlimab (BGB-A1217) • tiragolumab (RG6058)
    2ms
    Tumor microenvironment (TME) biomarkers of TIGIT and PD-L1 immune checkpoint blockade in cervical cancer: An exploratory biomarker analysis from SKYSCRAPER-04 (SKY04) study (AACR 2024)
    SKYSCRAPER-04 (NCT04300647) explored the clinical activity of Tiragolumab (T, anti-TIGIT) plus atezolizumab (A, anti-PD-L1) dual blockade (T+A) in patients (pts) with PD-L1+ cervical cancer. This exploratory analysis suggests that increased tumor immunity and mutation burden (TMB and PIK3CA-mut) correlates with improved ICB clinical outcomes. No biomarkers were clearly associated with tiragolumab outcome. These results are hypothesis generating and should be confirmed in an independent dataset.
    Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    PIK3CA mutation • PTEN mutation • TMB-L
    |
    FoundationOne® CDx
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    2ms
    Exploration of potential biomarkers correlated with efficacy of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) in 1L PD-L1+ non-small cell lung cancer (NSCLC) (AACR 2024)
    Anti-TIGIT MOA-related genes and signatures correlated with efficacy in ociperlimab + tislelizumab-treated 1L PD-L1+ NSCLC. Combining anti-TIGIT MOA-related factors with PD-L1 expression identified a subgroup of patients with improved efficacy.Table. Efficacy Analyses in Patient SubgroupsCutoff: aTop 1/3; bMedian; cTC≥25%
    Clinical • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CCR8 (C-C Motif Chemokine Receptor 8) • CD226 (CD226 Molecule)
    |
    PD-L1 expression • TIGIT expression
    |
    VENTANA PD-L1 (SP263) Assay
    |
    Tevimbra (tislelizumab) • ociperlimab (BGB-A1217)
    2ms
    AdvanTIG-302: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (clinicaltrials.gov)
    P3, N=660, Recruiting, BeiGene | Trial completion date: May 2025 --> Oct 2026 | Trial primary completion date: Jan 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab) • ociperlimab (BGB-A1217)